BEDFORD, Ohio, April 13 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories, Inc., announced the addition of Fluconazole injection 2 mg / mL in PVC flexible containers to its existing Fluconazole injection line. This product is AP rated and is equivalent to Diflucan(R) by Pfizer. Fluconazole injection is an antifungal agent indicated for oropharyngeal and esophageal candidiasis, cryptococcal meningitis, and is also indicated for the prophylaxis of candidiasis.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )
“In our continuing effort to offer the most comprehensive and cost effective line of injectables in the multisource industry, Bedford Laboratories is pleased to begin offering this product in PVC flexible containers. This product represents Bedford’s entry into the I.V. bag market and demonstrates our ongoing commitment to providing a broad based portfolio of products,” said David Gaugh, Vice President of Bedford Laboratories.
In addition to the glass vial presentations, Bedford Laboratories will supply Fluconazole injection as a sterile iso-osmotic solution containing 2mg / mL of fluconazole in 0.9% sodium chloride diluent in the following presentations: 200mg / 100mL in single-dose PVC flexible containers packaged in cartons containing 10 bags and 400mg / 200mL in single-dose PVC flexible containers packaged in cartons containing 10 bags.
Prescribing information is available upon request from the Bedford Laboratories’ professional services department at 800.521.5169, or from the company’s web site, www.bedfordlabs.com.
About Bedford Laboratories
Bedford Laboratories supplies the US and International markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.
About Boehringer Ingelheim Corporation
Boehringer Ingelheim Corporation based in Ridgefield, CT, is the US headquarters to seven subsidiaries and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and approximately 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
In 2007, Boehringer Ingelheim posted net sales of US $15.0 billion (10.9 billion euro) while spending approximately one-fifth of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information on the Boehringer Ingelheim Corporation, please visit http://us.boehringer-ingelheim.com.
CONTACT: Jason Kurtz, Bedford Laboratories, +1-440-201-3668,
jason.kurtz@boehringer-ingelheim.com
Web site: http://www.bedfordlabs.com/
